| Name | Title | Contact Details |
|---|
Accounting 501 (formerly Pery Consulting Group, founded by Rafe Pery) includes a team of 25 consultants with a broad range of experience in the non-profit sector from the day-to-day transactional accounting level up to the CFO level. Accounting 501 works exclusively in the non-profit sector and assists organizations that are experiencing rapid growth or operational challenges such as…a financial crisis, staffing transitions, accounting system clean-up, merger/reorganization, the need to establish and/or fine tune systems, policies, and procedures. At Accounting 501, we specialize in assisting organizations with complex private and public funding sources to maximize grants and contracts and to ensure compliance with grant requirements. We understand the importance of cost allocation as well as cost center reporting as key to meeting the goals of the organization.
San Diego FC is a Major League Soccer (MLS) expansion team set to begin play in 2025. Owned by Sir Mohamed Mansour through his family office, Man Capital, the club focuses on social impact, environmental sustainability, and youth development. It operates under the Right to Dream model, a globally recognized soccer academy system that emphasizes holistic athlete development and community engagement. The team will compete in MLS, with home games at Snapdragon Stadium. San Diego FC also features the Right to Dream Academy, which provides free education, housing, and soccer training to young athletes. This academy aims to foster athletic development, academic excellence, and personal growth, mirroring existing facilities in Ghana, Egypt, and Denmark. Additionally, the club engages in community programs that promote diversity and inclusion, targeting local residents and youth athletes from underserved communities. The ownership structure reflects a partnership between Mansour’s Man Capital and the Sycuan Tribe, blending global sports investment with local heritage.
With headquarters in the greater St. Louis region, UNCOMN provides Industry-Leading B2B Management and Technology Consulting Services. We are a diverse group of engineers, architects, analysts, hackers, and geeks who thrive on finding elegant solutions to wickedly complex organizational, logistic, process, data, and technical problems. In everything we do, we pursue truth, goodness, and beauty. We put people first and hire for the long-term, not for the contract. We put the right people in the right roles. We work with rigor, transparency, and excellence – doing whatever it takes while upholding unquestionable integrity, from start to finish. And we do so with the intention of making our team, clients, and communities better along the way. At UNCOMN, we arent just about profits and the bottom line. We uphold service before self, giving over receiving and social impact over siloing. Its our duty as industry experts to lead by example, share what we know and help create strong, vibrant communities in which we are proud to live and serve. We invest in and mentor for SixThirty CYBER, a business development program that offers cyber security-based technology startups with up to $250,000 of services each year. Through these services, the St. Louis regions top executives and chief information security officers provide hands-on training, mentoring and network opportunities to the startups key stakeholders.
We are the premier, professional rugby team in the South. The NOLA Gold is the New Orleans franchise of Major League Rugby.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.